The American College of Physicians recently recommended that women do not need to have a pelvic exam on an annual basis. Current evidence suggests that the pelvic exam is not helpful as a routine screening test for women with an average risk of developing ovarian cancer.
2015 marks the 15th anniversary of the Wisconsin Ovarian Cancer Alliance (WOCA), a Partner Member organization dedicated to overcoming ovarian cancer through education, advocacy, and awareness. When oncology nurse Joan Sagan was diagnosed with stage 3C ovarian cancer in 1999, she, along with sisters Kelli Zembruski and Sandi Wagner, realized there was an immediate need for ovarian cancer education in their home state of Wisconsin. While Joan knew from her role as an oncology nurse how devastating this disease can be, Kelli and Sandi knew very little about ovarian cancer. At this point, ovarian cancer was still known as the silent killer, with no symptom awareness. In May 2000, the Wisconsin Ovarian Cancer Alliance was officially founded, with the mission to educate the community about ovarian cancer and raise awareness about this horrible disease. Click the plus sign to read more.
(June 25, 2014) Research presented at the annual meeting of the American Society of Clinical Oncology earlier this month suggests that palliative care delivered at the time of cancer diagnosis improves survival. A randomized trial of palliative oncology care in 207 patients with advanced cancer and their caregivers showed that the risk of death at … Continued
(June 24, 2014) Earlier this month, researchers reported results of a Phase II trial which looked at efficacy and safety of a biweekly gemcitabine, carboplatin, and bevacizumab combination in patients with platinum-sensitive recurrent ovarian, peritoneal, or tubal cancer. The results, which were published online June 5, 2014 in the journal Gynecologic Oncology, showed that biweekly … Continued
On Monday, June 16, 2014, Dr. Douglas Levine of Memorial Sloan Kettering Cancer Center presented a free webinar focusing on research news that was presented at 2014’s medical meetings. In his hour-long presentation, he focused primarily on new ovarian cancer research that was presented at the American Society of Clinical Oncology’s annual meeting, which took … Continued
Promising new combination treatments for ovarian cancer Dr. Joyce Liu, MD, on behalf of researchers from the National Cancer Institute (NCI) and Dana Farber Cancer Institute (DFCI), presented striking results from a Phase II trial testing the combination of the PARP inhibitor olaparib and the anti-angiogenesis drug cediranib (which blocks tumors from creating new blood … Continued
Kelly Ripa Stars in Public Service Announcements for “QVC Presents Super Saturday LIVE,” Benefitting Ovarian Cancer Research Fund WEST CHESTER, Pa. (June 10, 2014) – Kelly Ripa is shopping to save lives as she fills up her bag with designer deals that will contribute to the cure for ovarian cancer. Ripa, one of the most … Continued
Posted by adavis on January 24, 2014 FOR IMMEDIATE RELEASE: January 24, 2014 Washington, DC—In response to a recent speech by Mike Huckabee, in which he stated that women use oral contraceptives because they “cannot control their libidos or their reproductive systems,” the Ovarian Cancer National Alliance issued the following statement from CEO Calaneet Balas: “In his quest … Continued
Posted by Laura Koontz on June 5, 2014 The 50th Annual Conference of the American Society of Clinical Oncology, held May 30 – June 3 in Chicago, featured a number of promising and thought provoking studies on ovarian cancer. Below is a brief summary of the most notable studies from the meeting. In the coming weeks, we’ll also post … Continued
(June 4, 2014) In a study presented at the American Society of Clinical Oncology annual meeting last week, researchers found that the combination of olaparib and cediranib (Recentin) kept recurrent ovarian cancer from worsening for almost nine months longer than treatment with olaparib alone. For this study, 90 women with recurrent ovarian cancer that was … Continued
Partnership is a word you’ll hear often from the board members of Caring Together, a Partner Member of the Alliance in eastern New York. The support group was organized in 1996 by a survivor and nurse practitioner named Debbie Cullinan. “As the support group continued to grow, women and their families had a strong desire … Continued
The Food and Drug Administration is seeking comments by June 11, 2014 on its review for Olaparib approval. Olaparib is an oral poly ADP-ribose polymerase (PARP) inhibitor that exploits DNA repair pathway deficiencies to preferentially kill cancer cells. AstraZeneca, the company that manufactures the drug, has submitted an application to the FDA for approval of … Continued
Get email updates about research news, action alerts, and ways to join the fight.
Our website uses cookies to ensure you get the best experience. By continuing to use this website, you indicate that you have read and agree to our Terms of Use and Privacy Policy.
